Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Ala advised the West Midlands Working Party meeting - through letter - that cryoprecipitate was "probably a safer product than Factor VIII concentrate in respect of transmission of AIDS".

Linked evidence
SHIN0000030 - Minutes of West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs meeting - 19 Jul 1983

Chronology Information

Date:

27 June 1983
Chapter/issue
Haemophilia Centres: Policies and Practice
Key Person(s)
Dr Fereydoun Ala

Documents

SHIN0000030 Minutes of West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs meeting 19 Jul 1983

pdf
(776.6 KB)
Download

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.